About the Event

Welcome To the TRP Targeted Selection & Drug Design Summit 2025

As radiopharmaceuticals continue to show sustained clinical efficacy within SSTR2 and PSMA we’ve seen a flurry of investment as the field looks towards novel targets and therapeutic design.

From targeting molecule to linker and chelator technologies, attendees joined us at the inaugural TRP Target Selection & Drug Design Summit, bringing together expert drug hunters and senior decision makers pioneering the field from medicinal chemistry, R&D, discovery, biology, radiochemistry, strategy and more.

Offering data driven insights, case study presentations and informative discussions to address the most pressing challenges and exciting opportunities across radiopharmaceutical target selection and drug design.

2025 Attendees Benefitted From:

https://targeted-radiopharma-target-selection-drug-design.com/wp-content/uploads/sites/998/2024/10/cropped-Untitled-design-73.png
https://targeted-radiopharma-target-selection-drug-design.com/wp-content/uploads/sites/998/2024/10/cropped-Untitled-design-73.png
https://targeted-radiopharma-target-selection-drug-design.com/wp-content/uploads/sites/998/2024/10/cropped-Untitled-design-73.png
https://targeted-radiopharma-target-selection-drug-design.com/wp-content/uploads/sites/998/2024/10/cropped-Untitled-design-73.png
https://targeted-radiopharma-target-selection-drug-design.com/wp-content/uploads/sites/998/2024/10/cropped-Untitled-design-73.png
https://targeted-radiopharma-target-selection-drug-design.com/wp-content/uploads/sites/998/2024/10/cropped-Untitled-design-73.png

Discovered the unique characteristics of a prime radiopharmaceutical target from receptor expression, radiosensitive tissues, stromal targeting and more with AstraZeneca, Ratio Tx and WARF Therapeutics

Revealed novel targets to unlock new therapeutic potential, exploring optimal drug design to target uPAR, B7-H3, CAIX from Monopar Tx, RadioPharm Theranostics and RayzeBio and debuting undisclosed target from Molecular Partners

Illuminated target mining technologies from proteomic analysis, artificial intelligence, machine learning and more to unlock entirely novel targets with AstraZeneca and UCLA

Assessed the use of well characterized ADC targets such as NECTIN-4 as well as unsuccessful ADC targets for use in radiopharmaceuticals from a commercial and technical lens with AstraZeneca

Explored the radiobiological and immunological response mechanisms to varying radiation types to guide optimal drug design as well as CAR-T combination approaches with University of Wisconsin

Transformed pharmacokinetics and biodistribution with cutting-edge targeting strategies from small molecule, mini protein, antibody fragments as well as linker & chelator technologies with Monopar Therapeutics and University of Wisconsin-Madison

2025 Event Guide Fast Download

Screenshot 2024-10-31 105333

Download the free PDF event guide for a full rundown of the 2025 sessions, saving options and more...